Integrase strand transfer inhibitor-associated diabetes mellitus: A case report

Int J STD AIDS. 2017 May;28(6):626-628. doi: 10.1177/0956462416675107. Epub 2016 Oct 12.

Abstract

Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavirenz to abacavir, lamivudine, and raltegravir. Hemoglobin A1C normalized without further need for exogenous insulin after raltegravir was switched back to efavirenz. In this case report, we will review a possible mechanism for INSTI-induced hyperglycemia and/or diabetes mellitus.

Keywords: HIV; Integrase inhibitors; diabetes mellitus; raltegravir.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Diabetes Mellitus / chemically induced*
  • Diabetes Mellitus / pathology*
  • Dideoxynucleosides / administration & dosage
  • Dideoxynucleosides / adverse effects
  • Drug Combinations
  • Glycated Hemoglobin / analysis
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Integrase Inhibitors / administration & dosage
  • HIV Integrase Inhibitors / adverse effects*
  • Humans
  • Lamivudine / administration & dosage
  • Lamivudine / adverse effects
  • Male
  • Raltegravir Potassium / administration & dosage
  • Raltegravir Potassium / adverse effects

Substances

  • Dideoxynucleosides
  • Drug Combinations
  • Glycated Hemoglobin A
  • HIV Integrase Inhibitors
  • abacavir, lamivudine drug combination
  • hemoglobin A1c protein, human
  • Lamivudine
  • Raltegravir Potassium